Customer Updates: Stryker Network Disruption > Read Now
Neuroform Atlas Stent System
Proven performance. Long-term results.
Neuroform Atlas® Stent System is the most extensively studied adjunctive stent on the market to date.* From 1-year primary endpoints to 3-year durability, the ATLAS IDE study highlights how Neuroform Atlas is safe and effective long-term.
ATLAS Study 3-year outcomes
Background
The ATLAS trial was a prospective, multicenter, single-arm, IDE study to evaluate the safety and effectiveness of the Neuroform Atlas Stent System for the treatment of wide-necked bifurcation aneurysms.
Anterior circulation cohort
Of the 182 patients initially enrolled in the anterior cohort, 146 were re assessable for the composite safety analysis. Due to differences between clinical and radiographic follow-up requirements, 44 patients at 24 months and 26 patients at 36 months were assessable for the composite effectiveness analysis.
Complete occlusion rate
Raymond-Roy 1
Primary safety outcome
Major stroke or neurological death
Primary efficacy outcome
RR1 without retreatment or significant parent artery stenosis
Retreatment
Delayed target aneurysm rupture
25
Centers in the US
146
Patients
6.1mm
Mean aneurysm size
1.2
Mean dome/neck ratio
Jankowitz B, Jadhav AP, Gross B, et al. Post-approval study 3-year outcomes of the Neuroform Atlas stent for the treatment of wide-necked intracranial aneurysms. J Neurointerv Surg. Published online January 30, 2026. doi:10.1136/jnis-2025-024547
* As of February 2026
"The results of the long-term assessment of Neuroform Atlas demonstrate its exceptional safety and efficacy in the treatment of both anterior and posterior wide neck bifurcation aneurysms, with favorable long-term occlusion rates, and no delayed target aneurysms ruptures which reinforces stent-assisted coiling as an effective short term aneurysm occlusion strategy with long term results comparable to flow diversion."
Dr. Brian Jankowitz, Co-PI of the ATLAS IDE Study
Posterior circulation cohort
Of the 116 patients initially enrolled in the posterior cohort, 101 were assessable for the composite safety analysis. Due to differences between clinical and radiographic follow-up requirements, 29 patients at 24 months and 24 patients at 36 months were assessable for the composite effectiveness analysis.
Complete occlusion rate
Raymond-Roy 1
Primary safety outcome
Major stroke or neurological death
Primary efficacy outcome
RR1 without retreatment or significant parent artery stenosis
Retreatment
Delayed target aneurysm rupture
25
Centers in the US
101
Patients
7.0mm
Mean aneurysm size
1.2
Mean dome/neck ratio
Jankowitz B, Jadhav AP, Gross B, et al. Post-approval study 3-year outcomes of the Neuroform Atlas stent for the treatment of wide-necked intracranial aneurysms. J Neurointerv Surg. Published online January 30, 2026. doi:10.1136/jnis-2025-024547
* As of February 2026
"The results of the long-term assessment of Neuroform Atlas demonstrate its exceptional safety and efficacy in the treatment of both anterior and posterior wide neck bifurcation aneurysms, with favorable long-term occlusion rates, and no delayed target aneurysms ruptures which reinforces stent-assisted coiling as an effective short term aneurysm occlusion strategy with long term results comparable to flow diversion."
Dr. Brian Jankowitz, Co-PI of the ATLAS IDE Study
ATLAS Study 1-year outcomes
Background
The ATLAS trial is a prospective, multicenter, single-arm, open-label study of unruptured, wide-necked intracranial aneurysms treated with the Neuroform Atlas stent and adjunctive coiling. All results are core-lab adjudicated.
Anterior circulation cohort
The pivotal ATLAS IDE study is the largest evaluation of its kind, including an anterior circulation cohort of 182 patients treated across 25 U.S. centers.
Complete occlusion rate
Raymond-Roy 1
Primary safety outcome
Major stroke or neurological death
Primary efficacy outcome
RR1 without retreatment or significant parent artery stenosis
Retreatment
25
Centers in the US
182
Patients
6.1mm
Mean aneurysm size
4.1mm
Mean neck width
Zaidat OO, Hanel RA, Sauvageau EA, et al. Pivotal Trial of the Neuroform Atlas Stent for Treatment of Anterior Circulation Aneurysm. Stroke. 2020; 51:2087 -2094.
* As of February 2026
In the ATLAS IDE anterior circulation aneurysm cohort premarket approval study, the Neuroform Atlas stent with adjunctive coiling met the primary end points and demonstrated high rates of long-term complete aneurysm occlusion at 12 months, with 100% technical success and <5% morbidity.
Posterior circulation cohort
The ATLAS IDE study included a posterior circulation cohort of 116 patients with wide-necked intracranial aneurysms, representing the largest clinical evaluation of the Neuroform Atlas Stent in this patient population.
Complete occlusion rate
Raymond-Roy 1
Primary safety outcome
Major stroke or neurological death
Primary efficacy outcome
RR1 without retreatment or significant parent artery stenosis
Retreatment
25
Centers in the US
116
Patients
7.1mm
Mean aneurysm size
4.7mm
Mean neck width
Jankowitz BT, Jadhav AP, Gross B, et al, Pivotal trial of the Neuroform Atlas stent for treatment of posterior circulation aneurysms: one-year outcomes, Journal of NeuroInterventional Surgery 2022;14:143-148.
In the ATLAS IDE aneurysm cohort premarket approval study, Y-stent–assisted coiling with Neuroform demonstrated high rates of complete aneurysm occlusion at 12 months, with low rates of morbidity.
Y-stenting subset
A subgroup analysis was conducted among subjects treated with Y-stent-assisted coiling in the ATLAS IDE study. Enrollment was not stratified by stenting technique. The most common aneurysm locations in this subgroup were the basilar apex (56.7%), anterior communicating artery (20.0%), and middle cerebral artery bifurcation (11.7%).
Complete occlusion rate
Raymond-Roy 1
Primary safety outcome
Major stroke or neurological death
Primary efficacy outcome
RR1 without retreatment or significant parent artery stenosis
Retreatment
25
Centers in the US
60
Patients
6.7mm
Median aneurysm size
4.3mm
Median neck width
Jadhav AP, Desai SM, Jovin TG, et al. Y-Stent-Assisted Coiling of Wide-Necked Intracranial Aneurysms With the Neuroform Atlas Stent System. Stroke Vasc Interv Neurol. 2022;3(1):e000437. Published 2022 Aug 31. doi:10.1161/SVIN.122.000437
In the ATLAS IDE aneurysm cohort premarket approval study, Y-stent–assisted coiling with Neuroform demonstrated high rates of complete aneurysm occlusion at 12 months, with low rates of morbidity.
MCA subset
Of the anterior circulation patients enrolled in the ATLAS IDE study, 35 patients underwent treatment for middle cerebral artery (MCA) aneurysms and were included in a subgroup analysis.
Complete occlusion rate
Raymond-Roy 1
Primary safety outcome
Major stroke or neurological death
Retreatment
25
Centers in the US
35
Patients
27 MCA bifurcation, 5 M1, 3 M2
6.0mm
Mean aneurysm size
4.4mm
Mean neck width
Hanel RA, Yoon N, Sauvageau E, et al. Neuroform Atlas Stent for Treatment of Middle Cerebral Artery Aneurysms: 1-Year Outcomes From Neuroform Atlas Stent Pivotal Trial. Neurosurgery. 2021;89(1):102-108. doi:10.1093/neuros/nyab090
Stent-assisted coiling with the Neuroform Atlas Stent is a viable alternative to clipping for selected MCA aneurysms. Complete aneurysm occlusion rates have improved compared to historical data. Proper case selection can lead to acceptable endovascular results.
Jailing vs. recrossing subset
A total of 298 aneurysms were treated with Neuroform Atlas stent-assisted coiling across 25 centers in the ATLAS IDE study. Procedural technique, including jailing or re-crossing, was selected at the operator's discretion.
Complete occlusion rate (jailing)
N=182 (62%)
RR1 at 12 months DSA
Complete occlusion rate (recrossing)
N=101 (34%)
RR1 at 12 months DSA
25
Centers in the US
298
Total patients
- Similar aneurysm size and location were observed between the two groups
- No statistically significant difference in the number of coils used or the duration of the procedure.
- No statistically significant difference in occlusion rate or safety rate at 12 months
Snyder T, Jankowitz B, Zaidat OO, et al. Neuroform Atlas stent-assisted coiling: jailing versus re-crossing techniques. J Neurointerv Surg. Published online March 4, 2026. doi:10.1136/jnis-2025-024541. * As of February 2026
There were no significant differences in safety or efficacy for SAC between the jailing or re-crossing technique.
PP-000325
"Atlas was designed to be simple to use and highly effective, with pinpoint accuracy and the lowest metal-to-artery ratio of any device on the US market."
Dr. Brian Jankowitz
We are driven by clinical evidence and committed to proving the safety and effectiveness of our products in treating the toughest stroke cases.
Contact us.
Thank you for your submission.
* The ATLAS study was sponsored by Stryker.
This document is intended solely for the use of healthcare professionals.
A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.
Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Neuroform Atlas, Stryker. All other trademarks are trademarks of their respective owners or holders.
The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker’s trademark or other intellectual property rights concerning that name or logo.
AP005074 v3.0